Document text
byNicolas Hulscher, MPHA newly published two-part scientific study raises major alarms about an issue that has received remarkably little scrutiny:What happens when blood from COVID-19-vaccinated donors is transfused into another person?Blood banks routinely screen donations for recognized infectious threats. Yet the current blood supply is not routinely screened for vaccine-derived mRNA, spike protein, plasmid DNA, amyloid, fibrin-microclot complexes, or other relevant vaccine-associated constituents.Our newly published two-part series investigates this blind spot from two complementary directions. The two studies were authored by James A. Thorp, MD; Claire Rogers, MSPAS, PA-C; R. Clinton Ohlers, PhD; M. Nathaniel Mead, PhD; Nicolas Hulscher, MPH (myself); Kirstin Cosgrove, CCRA; Sierra Hamm, RN; David Speicher, PhD; and Steven Hatfill, MD, M Med.Part I: Serious Post-Transfusion Complications in Nine Unvaccinated PatientsPotential Implications of COVID-19 Vaccination for Blood Donation: A Retrospective Case Series and Literature Review—Part I of IIPart Ipresents a retrospective, hypothesis-generating case series ofnine individuals who had not received a COVID-19 vaccine and subsequently experienced serious medical events after receiving blood transfusions.Reported complications includedthromboembolic disease, progressive clotting disorders, myocarditis, pericardial disease, disseminated intravascular coagulation, multi-organ system failure, and death.We concluded that these cases, together with the existing literature, raise sufficient concern to warrant direct investigation of whether biologically active vaccine-derived constituents may be present in donated blood:This study suggests that blood donated by COVID-19-vaccinated individuals may contain biologically active vaccine-derived constituents that could cause adverse clinical outcomes. The case reports and cited studies identify questions that warrant further investigation. All the pathogenic components of the COVID-19 vaccine or byproducts from it, have been found in several studies to be circulating in the blood of vaccinated donors. Healthcare providers must honor the ethical principles of patient autonomy and non-maleficence and support patients’ requests for autologous and directed designated donor blood. Screening blood donations for the presence of spike protein, amyloid, fibrin-microclot complexes, vaccine-derived mRNA, and plasmid DNA using quantitative assays and PCR-based methods should be considered for further evaluation by relevant public health and regulatory authorities, including the CDC and FDA.Part II: Extraordinary Blood, Clotting, and Neurological Safety SignalsPotential Implications of COVID-19 Vaccination for Blood Donation: Part II—Analysis of VAERS and Review of the LiteraturePart IIexpands the investigation to the CDC/FDA Vaccine Adverse Event Reporting System, analyzing reports fromJanuary 1, 1990 through June 26, 2026and comparing COVID-19 vaccines with influenza vaccines, DPT-containing vaccines, and all non-COVID vaccines combined.The analysis identified statistically significant safety signals across every investigated endpoint, including reported rate ratios reaching:Hemorrhage: up to 101-foldHemorrhage in pregnancy: up to 108-foldBlood transfusion: up to 62-foldPost-transfusion complications: up to 30-foldHypercoagulable biomarkers: up to 452-foldThrombotic events: up to 1,221-foldParkinson’s disease: up to 282-foldCreutzfeldt-Jakob disease: up to 1,333-foldPrion disease: 60-foldThese signals are particularly important because they overlap with many of the same clinical patterns observed in Part I, includingthrombosis, hemorrhage, DIC, and multi-organ dysfunction.Part I identifies a series of serious post-transfusion events that demand investigation. Part II identifies striking pharmacovigilance signals involving many of the same biological systems, particularly clotting, hemorrhage, transfusion complications, and multi-organ dysfunction.To preserve global blood-supply integrity, regulatory frameworks should move rapidly to implement direct quantitative spike-protein screening and high-sensitivity digital PCR testing for vaccine-derived genetic material across donor networks, while also investigating whether these constituents remain biologically active after donation, storage, processing, and transfusion.Nicolas Hulscher, MPHEpidemiologist and Foundation Administrator, McCullough FoundationSupport our mission:mcculloughfnd.orgPlease consider following both theMcCullough Foundationandmy personal accountonX(formerly Twitter) for further content.Subscribe now